We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
-9.6%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$300M
AUM Growth
+$22.5M
Cap. Flow
+$70.6M
Cap. Flow %
23.49%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
NTGN
Neon Therapeutics, Inc. Common Stock
NTGN
+$133M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$33.2M
2
VYGR icon
Voyager Therapeutics
VYGR
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
1
Voyager Therapeutics
VYGR
$189M
$154M 51.35%
7,891,176
-1,500,000
-16% -$29.6M
NTGN
2
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$123M 40.88%
+9,741,636
New +$133M
JNCE
3
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$23.4M 7.78%
3,048,780
– –
MYOK
4
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-680,272
Closed -$33.2M

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q2 2018 Portfolio in Review

As of Q2 2018, TRV GP III held 4 positions worth $300M, up 8.1% from $278M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III deployed $70.6M of net new capital in Q2 2018, opening 1 new position. Its largest new stake was Neon Therapeutics, Inc. Common Stock: 9,741,636 shares worth $123M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Voyager Therapeutics, an estimated $29.6M trimmed.

  • TRV GP III's largest Q2 2018 buy was Neon Therapeutics, Inc. Common Stock: 9,741,636 shares worth $123M.
  • TRV GP III's biggest Q2 2018 reduction was Voyager Therapeutics, cutting an estimated $29.6M.
  • TRV GP III fully exited MyoKardia, Inc. Common Stock in Q2 2018, selling an estimated $33.2M.
  • TRV GP III's ten largest holdings make up 100% of its $300M portfolio in Q2 2018.
  • TRV GP III opened 1 new position and closed 1 in Q2 2018.
  • TRV GP III's portfolio value rose 8.1% quarter-over-quarter to $300M.

Based on TRV GP III's 13F filing for Q2 2018, filed 7 Aug 2018.